Business
Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen
About this update from Cerus Corporation
[{"type":"text","content":" CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients.\n\nInitiated in March 2020, the study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; Vaccine Research and Development Laboratory, University of California, Irvine, CA; and Enable Biosciences, San Francisco, CA.\n\nThe study of hospitalized patients with documented COVID-19 pneumonia enrolled 15 subjects who received INTERCEPT-treated CCP and 30 matched controls who received standard therapy without CCP transfusion. Of the 15 patients treated with INTERCEPT-treated CCP, 14 (93.3%) responded and were alive at study day 28. Three patients were severely immune-compromised. Among the 30 matched control patients, 6 (20%) died by study day 28.\n\n“The study summarizes the successful collaboration with the University Hospital of Basel, Cerus, and the other California-based research teams, generating important data to define CCP virus-neutralizing efficacy at the onset of the COVID-19 pandemic. We are encouraged by the patients’ responses to INTERCEPT-treated CCP and the preservation of neutralizing antibodies in INTERCEPT-treated CCP. The data from this study demonstrate the ability to identify effective CCP during epidemics that, with pathogen reduction to decrease the risk of transfusion-transmitted disease, can be rapidly introduced into routine practice,” said Dr. Laurence Corash, Cerus’ chief scientific officer.\n\nTo view the oral presentation on Saturday, December 5, click here: https://ash.confex.com/ash/2020/webprogram/Paper136180.html\n\nAbout University Hospital of Basel and the Regional Swiss Red Cross Blood Transfusion Center, Basel, Switzerland.\n\nThe University Hospital of Basel is a specialized medical research and patient care facility. The Regional Swiss Red Cross Blood Transfusion Center, ...